Lip Clinical Trials

412 recruitingLast updated: May 21, 2026

There are 412 actively recruiting lip clinical trials across 70 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Houston, Texas, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Lip Trials at a Glance

412 actively recruiting trials for lip are listed on ClinicalTrialsFinder across 6 cities in 70 countries. The largest study group is Not Applicable with 138 trials, with the heaviest enrollment activity in Beijing, Houston, and Chicago. Lead sponsors running lip studies include National Cancer Institute (NCI), China Immunotech (Beijing) Biotechnology Co., Ltd., and Beijing Tiantan Hospital.

About Lip Clinical Trials

Looking for clinical trials for Lip? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lip trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lip clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 412 trials

Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 2

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled51 locationsNCT07195734
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled222 locationsNCT05136196
Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled251 locationsNCT06422806
Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled559 locationsNCT07517263
Recruiting

Lysosomal Acid Lipase Deficiency in Risk Groups

Lysosomal Acid Lipase Deficiency
AstraZeneca1,200 enrolled4 locationsNCT07455864
Recruiting
Not Applicable

A Study to Evaluate the Safety and Performance of Dr Korman Laboratories' Hyaluronic Acid Filler 20 mg/mL With Lidocaine for Lip Augmentation

Lip Augmentation
Dr. Korman Laboratories Ltd.75 enrolled2 locationsNCT07204691
Recruiting
Phase 2

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8+13 more
ECOG-ACRIN Cancer Research Group189 enrolled676 locationsNCT02734537
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Not Applicable

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

Cardiovascular DiseasesInflammationDyslipidemias
Universidade Federal Fluminense48 enrolled1 locationNCT06183307
Recruiting
Not Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

PrediabetesPrehypertensionOverweight/Obesity+1 more
Beijing Anzhen Hospital1,400 enrolled3 locationsNCT07372729
Recruiting
Phase 3

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Hyperlipidemia
Beijing Suncadia Pharmaceuticals Co., Ltd900 enrolled1 locationNCT07230730
Recruiting
Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled177 locationsNCT06589804
Recruiting
Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled6 locationsNCT06980038
Recruiting
Not Applicable

Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing

Cleft Lip and Palate
Centre Hospitalier Universitaire, Amiens30 enrolled1 locationNCT03065686
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Not Applicable

New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases

HypertensionCardiovascular Disease PreventionHyperlipidemia+5 more
New Taipei City Medical Association4,162 enrolled1 locationNCT07588256